Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 15Sarcoma, Ewing 10Neuroblastoma 7Rhabdomyosarcoma 6Osteosarcoma 6Gliosarcoma 6Glioblastoma 6Brain Neoplasms 6Astrocytoma 6Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Central Nervous System Neoplasms 5Glioma 4Wilms Tumor 3Sarcoma, Clear Cell 3Rhabdoid Tumor 3Recurrence 3Desmoplastic Small Round Cell Tumor 3Dendritic Cell Sarcoma, Interdigitating 3Burkitt Lymphoma 3Testicular Neoplasms 2Retinoblastoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Optic Nerve Glioma 2Oligodendroglioma 2Myoepithelioma 2Meningeal Carcinomatosis 2Malignant mesenchymal tumor 2Lymphoma 2

Interventions

seclidemstat 2pazopanib 2Topotecan 2Ifosfamide 2Doxorubicin 2Cyclophosphamide 2selinexor 1Radiotherapy 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Histiocytoma, Angiomatoid Fibrous × Topotecan × Sarcoma × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡